Aperiomics Closes $1.8M Series A Funding Round

Aperiomics, a Sterling, Va.-based biotech company combining advancements in science, technology, closed a Series A funding round totaling $1.8m. The round was led by VentureSouth with participation from Pipeline Angels, Propel(x) and high net worth individuals. The company intends to use the funds to increase the number of patients they serve and clinicians they partner with, and make major investments in research and development.”

Aperiomics combines the latest advancements in science, technology, and medicine to change the way healthcare providers identify causes of infection. With the only microbial database of its kind and superior data analytics, we are able to precisely detect pathogens with 97% sensitivity and 99.99% specificity. The Xplore-Patho test gives clinicians an unprecedented advantage in identifying infections that often evade diagnosis.
The only company able to identify every bacterium, virus, fungus, and parasite known to modern science, Aperiomics has created a new gold standard with its Xplore-Patho test.

If you’d like to learn more about Aperiomics’ and see the news article, click here